BH3:FRA
PTC Therapeutics, Inc.
55,00 €
arrow_downward
-0,61%(-0,34) 1D
9 tet, 10:00:00 m.d., GMT+2 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BH3...
Hap
55,00 €
I lartë
55,00 €
I ulët
55,00 €
Kapitalizimi i tregut
5,40Â mld
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
77,02 €
Minimumi 52-javor
52,50 €
Numri i punonjësve
991
Hap
55,00 €
I lartë
55,00 €
I ulët
55,00 €
Kapitalizimi i tregut
5,40Â mld
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
77,02 €
Minimumi 52-javor
52,50 €
Numri i punonjësve
991
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
MarketBeat
·
12 orë më parë
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages
Investing.com Canada
·
21 orë më parë
Form 4 PTC Therapeutics Inc For: 9 October By Investing.com
Stock Titan
·
23 orë më parë
Officer Mark Elliott Boulding proposes selling 192 shares of PTC Therapeutics (Nasdaq: PTCT).
Yahoo Finance
·
2 ditë më parë
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
Profili
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
Rreth PTC Therapeutics, Inc.
Drejtori ekzekutivMatthew B. Klein
Punonjësit991
Themeluar më1 jan 1998
SeliaWarren, New Jersey, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtiptcbio.com